Attached files
file | filename |
---|---|
8-K - FORM 8-K - HARROW HEALTH, INC. | c07126e8vk.htm |
Exhibit 99.1
News Release
Transdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer
and President
and President
LA JOLLA, CA October 21, 2010 Transdel Pharmaceuticals, Inc. (OTCBB: TDLP), a specialty
pharmaceutical company focused on developing topically administered products using its proprietary
transdermal delivery platform, today announced the appointment of John N. Bonfiglio, Ph.D. as Chief
Executive Officer and President. Dr. Bonfiglio will also serve as a director on Transdels Board
of Directors.
With over 27 years of pharmaceutical industry experience, Dr. Bonfiglio brings to Transdel his
background in working with pharmaceutical companies during the development stage as well as those
with commercialized products. Given his experience, the Board of Directors is extremely pleased to
have Dr. Bonfiglio join Transdel to continue to drive the vision of the Company.
I believe that Transdel has the opportunity to become a successful pharmaceutical company, stated
Dr. Bonfiglio. Our lead product, Ketotransdel®, has an opportunity to be the first topical
ketoprofen product approved in the U.S. and also to become a best in class product in the growing
topical NSAID market. I am looking forward to leading this talented team in growing the Companys
pharmaceutical and cosmeceutical businesses. Increasing shareholder value is number one on my
agenda.
Most recently, Dr. Bonfiglio worked as the President and Chief Executive Officer of Argos
Therapeutics in Durham, NC and prior to that he was the Chief Executive Officer of The Immune
Response Corporation in Carlsbad, CA. He was also the Chief Executive Officer of Peregrine
Pharmaceuticals and held senior management positions with Cypress Biosciences, Baxter Healthcare
and Allergan, Inc.
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company developing
non-invasive, topically delivered products. The Companys innovative-patented Transdel cream
formulation technology is designed to facilitate the effective penetration of a variety of products
through the tough skin barrier. Ketotransdel®, the Companys lead pain product candidate, has
completed a Phase 3 clinical trial and utilizes the Transdel technology to deliver the active
drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the
underlying tissues where the drug exerts its well-known anti-inflammatory and analgesic effects.
The Company intends to leverage its Transdel platform technology to expand and create a portfolio
of topical products for a variety of indications. The Company is actively pursuing partnerships
with companies to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical
products. For more information, please visit http://www.transdelpharma.com.
Safe Harbor Statement
The Company cautions you that the statements included in this press release that are not a
description of historical facts are forward-looking statements. These include statements regarding:
the Companys interpretation of the results of its Phase 3 clinical trial for
Ketotransdel®; the Companys ability to obtain regulatory approval to market
Ketotransdel; and the Companys ability to complete additional development activities for products
utilizing its proprietary transdermal delivery platform. Actual results may differ materially from
those set forth in this press release due to the risks and uncertainties inherent in the Companys
business, including, without limitation: the FDA may not agree with the Companys interpretation of
the results of the Phase 3 clinical trial for Ketotransdel or may challenge the adequacy of the Companys
clinical trial design or the execution of the clinical trial; the FDA may require the Company to
complete additional clinical trials for Ketotransdel® before the Company can submit a
505(b)(2) NDA application; the results of any future clinical trials may not be favorable and the
Company may never receive regulatory approval for Ketotransdel®; and the Companys
current need to raise additional funding to complete its product development and clinical trial
plans. More detailed information about the Company and the risk factors that may affect the
realization of forward-looking statements is set forth in the Companys filings with the Securities
and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form
10-Q filed with the SEC. Such documents may be read free of charge on the SECs web site at
www.sec.gov. You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and the Company undertakes no obligation to revise or
update this press release to reflect events or circumstances after the date hereof. This caution is
made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform
Act of 1995.
Contact:
John Lomoro, Chief Financial Officer
Transdel Pharmaceuticals, Inc.
858-457-5300
johnl@transdelpharma.com
John Lomoro, Chief Financial Officer
Transdel Pharmaceuticals, Inc.
858-457-5300
johnl@transdelpharma.com